HRP20181320T8 - Ljudska anti-tau protutijela - Google Patents

Ljudska anti-tau protutijela

Info

Publication number
HRP20181320T8
HRP20181320T8 HRP20181320TT HRP20181320T HRP20181320T8 HR P20181320 T8 HRP20181320 T8 HR P20181320T8 HR P20181320T T HRP20181320T T HR P20181320TT HR P20181320 T HRP20181320 T HR P20181320T HR P20181320 T8 HRP20181320 T8 HR P20181320T8
Authority
HR
Croatia
Prior art keywords
human anti
tau antibodies
tau
antibodies
human
Prior art date
Application number
HRP20181320TT
Other languages
English (en)
Croatian (hr)
Inventor
Feng Chen
Jan Grimm
Jean-Luc BAERISWYL
Roger Nitsch
Christoph Hock
Original Assignee
Biogen International Neuroscience Gmbh
University Of Zurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience Gmbh, University Of Zurich filed Critical Biogen International Neuroscience Gmbh
Publication of HRP20181320T1 publication Critical patent/HRP20181320T1/hr
Publication of HRP20181320T8 publication Critical patent/HRP20181320T8/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
HRP20181320TT 2010-10-11 2011-10-11 Ljudska anti-tau protutijela HRP20181320T8 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39175110P 2010-10-11 2010-10-11
EP10013494 2010-10-11
PCT/IB2011/002786 WO2012049570A1 (en) 2010-10-11 2011-10-11 Human anti-tau antibodies
EP11797115.0A EP2627672B1 (en) 2010-10-11 2011-10-11 Human anti-tau antibodies

Publications (2)

Publication Number Publication Date
HRP20181320T1 HRP20181320T1 (hr) 2018-10-19
HRP20181320T8 true HRP20181320T8 (hr) 2018-12-14

Family

ID=43602869

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181320TT HRP20181320T8 (hr) 2010-10-11 2011-10-11 Ljudska anti-tau protutijela

Country Status (23)

Country Link
US (6) US8940272B2 (enExample)
EP (1) EP2627672B1 (enExample)
JP (2) JP2014503178A (enExample)
CN (1) CN103339146B (enExample)
AU (1) AU2011315181B2 (enExample)
BR (1) BR112013008765B8 (enExample)
CA (1) CA2813493C (enExample)
CY (1) CY1120951T1 (enExample)
DK (1) DK2627672T3 (enExample)
EA (1) EA031698B1 (enExample)
ES (1) ES2686550T3 (enExample)
HR (1) HRP20181320T8 (enExample)
IL (1) IL225670B (enExample)
LT (1) LT2627672T (enExample)
MX (1) MX345092B (enExample)
NZ (1) NZ609984A (enExample)
PL (1) PL2627672T3 (enExample)
PT (1) PT2627672T (enExample)
SG (1) SG189174A1 (enExample)
SI (1) SI2627672T1 (enExample)
TR (1) TR201812636T4 (enExample)
WO (1) WO2012049570A1 (enExample)
ZA (1) ZA201303175B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
NZ626269A (en) 2011-12-20 2016-06-24 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
KR20150036346A (ko) 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
EA035976B1 (ru) * 2012-08-16 2020-09-08 АйПИЕРИАН, ИНК. Анти-tau антитела для лечения таупатий
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
ES2816700T3 (es) * 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG10201707855YA (en) * 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
WO2014150877A2 (en) * 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EA039554B1 (ru) * 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
MX384909B (es) * 2013-11-27 2025-03-14 Ipierian Inc Un anticuerpo anti-tau para usarse al tratar una tauopatía.
JP6608827B2 (ja) 2013-12-20 2019-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヒト化抗タウ（ｐＳ４２２）抗体及び使用方法
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
KR20170023124A (ko) * 2014-06-26 2017-03-02 얀센 백신스 앤드 프리벤션 비.브이. 미세소관-연관 단백질 타우에 특이적으로 결합하는 항체 및 항원-결합 단편
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US10556946B2 (en) 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof
EP3760235A1 (en) * 2014-09-30 2021-01-06 Washington University Tau kinetic measurements
EP3204411A4 (en) * 2014-10-10 2018-03-28 National Research Council of Canada Anti-tau antibody and uses thereof
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016137950A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
WO2016164530A1 (en) * 2015-04-07 2016-10-13 University Of Maryland, College Park Compositions and methods for high throughput protein sequencing
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
EP3313877B1 (en) 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN105388302A (zh) * 2015-12-22 2016-03-09 中国医学科学院输血研究所 一种人免疫球蛋白制品中Tau蛋白抗体含量的检测方法
WO2017157961A1 (en) 2016-03-14 2017-09-21 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
AU2017276656A1 (en) 2016-06-07 2018-12-13 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030754C (en) * 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CN109562167A (zh) 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
WO2018049219A1 (en) * 2016-09-08 2018-03-15 Regenerative Research Foundation Bi-functional anti-tau polypeptides and use thereof
AU2017359944B2 (en) 2016-11-15 2024-07-18 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018178077A1 (en) * 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
CA3055866A1 (en) * 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Methods for detection of tau protein aggregation modulating compounds
KR20190133162A (ko) 2017-03-28 2019-12-02 제넨테크, 인크. 신경퇴행성 질병의 치료 방법
PE20200695A1 (es) * 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2018231254A1 (en) * 2017-06-16 2018-12-20 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
MX2020001855A (es) 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
AU2018345523B2 (en) 2017-10-02 2021-10-21 Merck Sharp & Dohme Llc Chromane monobactam compounds for the treatment of bacterial infections
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
CA3084098A1 (en) * 2017-12-04 2019-06-13 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019113711A1 (en) 2017-12-14 2019-06-20 University Of Ottawa Exosome packaging and targeted autophagy
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
JOP20200215A1 (ar) 2018-03-05 2020-09-03 Janssen Pharmaceutica Nv الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
CN111918875A (zh) * 2018-03-11 2020-11-10 库罗什·沙帕桑 构象-特异性的抗神经毒性tau蛋白的抗体
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
AU2019377595A1 (en) * 2018-11-08 2021-05-27 Prothena Biosciences Limited Antibodies recognizing tau
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP3946605A1 (en) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
KR20220034733A (ko) * 2019-05-27 2022-03-18 더 유니버시티 오브 브리티쉬 콜롬비아 타우의 입체형태-특이적 에피토프, 이에 대한 항체 및 이와 관련된 방법
CA3148740A1 (en) 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
US12331131B2 (en) 2019-09-20 2025-06-17 Navi Bio-Therapeutics, Inc. Personalized cancer immunotherapy
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
US20250134952A1 (en) 2021-09-20 2025-05-01 Institut National de la Santé et de la Recherche Médicale Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
JP2025512740A (ja) 2022-03-14 2025-04-22 ジェネンテック， インコーポレイテッド 音声分析に基づく神経変性疾患の予測
JP2025525371A (ja) 2022-06-21 2025-08-05 ジェネンテック， インコーポレイテッド 音声分析に基づくアルツハイマー病（ａｄ）の長期的進行の検出
IL317876A (en) 2022-07-29 2025-02-01 Alector Llc Transferrin receptor antigen binding domains and their uses
CA3261511A1 (en) 2022-07-29 2024-02-01 Alector Llc CD98HC ANTIGEN BINDING DOMAINS AND THEIR USES
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体
CN117106081B (zh) * 2023-09-28 2024-05-07 北京凯祥弘康生物科技有限公司 一种抗nfl蛋白的捕获抗体
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
CN117969825A (zh) * 2024-02-18 2024-05-03 上海信利健康管理有限公司 一种人尿液中的磷酸化Tau蛋白的胶体金免疫层析检测卡及其制备方法
CN120174021A (zh) * 2024-03-08 2025-06-20 百奥赛图(北京)医药科技股份有限公司 一种tau基因修饰的非人动物
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
CN119661705B (zh) * 2024-11-22 2025-06-24 上海伯杰医疗科技股份有限公司 一种抗p-Tau217蛋白单克隆抗体及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
WO1993008302A1 (en) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
JPH07503132A (ja) * 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE165866T1 (de) 1992-12-14 1998-05-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
PT737208E (pt) 1993-12-21 2006-12-29 Innogenetics Nv Anticorpos monoclonais específicos para phf-tau, hibridomas que os segregam, reconhecimento de antigénios por estes anticorpos e suas aplicações
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
WO1998041645A1 (en) 1997-03-14 1998-09-24 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
EP1425694A2 (en) * 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
WO2003017918A2 (en) 2001-08-24 2003-03-06 Universität Zürich A method of inducing the formation of neurofibrillary tangles in transgenic animals
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
US20060240485A1 (en) 2003-04-24 2006-10-26 Universitat Zurich Method of monitoring immunotherapy
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US7083854B1 (en) 2005-05-10 2006-08-01 Cornell Research Foundation, Inc. Fibers from polymer nanoclay nanocomposites by electrospinning
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
CA2737267A1 (en) * 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
BR112013008333B1 (pt) 2010-10-07 2022-10-11 Ac Immune S.A. Anticorpo, composição farmacêutica, hibridoma, polinucleotídeo, método de diagnóstico in vitro e usos do anticorpo
MX345092B (es) 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120323214A1 (en) 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
ES2816700T3 (es) 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos

Also Published As

Publication number Publication date
AU2011315181B2 (en) 2016-07-28
EP2627672B1 (en) 2018-08-01
EA201390453A1 (ru) 2013-08-30
CA2813493A1 (en) 2012-04-19
WO2012049570A1 (en) 2012-04-19
SG189174A1 (en) 2013-05-31
BR112013008765B8 (pt) 2023-05-02
EP2627672A1 (en) 2013-08-21
MX2013003879A (es) 2014-07-09
IL225670A0 (en) 2013-06-27
NZ609984A (en) 2015-05-29
CN103339146A (zh) 2013-10-02
CY1120951T1 (el) 2019-12-11
CN103339146B (zh) 2017-09-01
LT2627672T (lt) 2018-12-10
MX345092B (es) 2017-01-17
DK2627672T3 (en) 2018-08-27
PL2627672T3 (pl) 2018-11-30
BR112013008765B1 (pt) 2022-07-12
US20120087861A1 (en) 2012-04-12
ES2686550T3 (es) 2018-10-18
TR201812636T4 (tr) 2018-09-21
US20150252102A1 (en) 2015-09-10
CA2813493C (en) 2019-07-09
US9605059B2 (en) 2017-03-28
ZA201303175B (en) 2021-05-26
HRP20181320T1 (hr) 2018-10-19
US8940272B2 (en) 2015-01-27
JP6300842B2 (ja) 2018-03-28
US20130295021A1 (en) 2013-11-07
JP2016138102A (ja) 2016-08-04
BR112013008765A2 (pt) 2020-09-15
AU2011315181A1 (en) 2013-05-09
US20180002409A1 (en) 2018-01-04
JP2014503178A (ja) 2014-02-13
IL225670B (en) 2018-04-30
PT2627672T (pt) 2018-11-16
US20190233506A1 (en) 2019-08-01
SI2627672T1 (sl) 2018-10-30
US20210238265A1 (en) 2021-08-05
EA031698B1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
HRP20181320T1 (hr) Ljudska anti-tau protutijela
SMT202000512T1 (it) Anticorpi anti-tau umani
DK2580243T3 (da) Antibodies against human cd38
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
PT2406284T (pt) Anticorpos anti-bcma
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO6791565A2 (es) Anticuerpos anti-notch1
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
ME02224B (me) Antikancerski fuzioni protein
EP2614745A4 (en) BRACELET
CO6841994A2 (es) Anticuerpos
DK2590565T3 (da) Blodprøvetagning
FR2965717B1 (fr) Fauteuil roulant
FR2965715B1 (fr) Fauteuil roulant
BR112013014731A2 (pt) tamavidina modificada
DK2651979T3 (da) Humane anti-sod1-antistoffer
ES1072200Y (es) Pañal
ES1072596Y (es) Pulsera
FIU20100211U0 (fi) Kestovaippa
DK2368783T3 (da) Kørestol